Zepbound

The brand name for tirzepatide (5 mg, 10 mg, 15 mg weekly injection) approved by the FDA in November 2023 for chronic weight management in adults with obesity or overweight with a weight-related comorbidity. Manufactured by Eli Lilly. SURMOUNT-1 and SURMOUNT-2 trials demonstrated average body weight reductions of 15.0–22.5% over 72 weeks at the highest dose — establishing it as the most effective approved pharmacotherapy for obesity and exceeding all prior weight loss medications in head-to-head and indirect comparisons.